Use of the monoclonal antibody MOC‐31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology

MOC‐31 is an established immunologic marker with which to detect adenocarcinomas. The objective of the current study was to evaluate the use of MOC‐31 in the diagnosis of metastatic adenocarcinoma in effusion specimens.

[1]  B. Xie,et al.  Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry , 2011, Diagnostic cytopathology.

[2]  Ying Sun,et al.  Diagnostic Utility of MOC-31, HBME-1 and MOC-31mRNA in Distinguishing Between Carcinoma Cells and Reactive Mesothelial Cells in Pleural Effusions , 2009, Acta Cytologica.

[3]  S. Masood,et al.  Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis , 2009, Diagnostic cytopathology.

[4]  J. Lee,et al.  Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks , 2009, Diagnostic cytopathology.

[5]  P. Athanassiadou,et al.  Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: An immunocytochemical study , 2009, Pathology & Oncology Research.

[6]  D. Coffey,et al.  Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? , 2009, Archives of pathology & laboratory medicine.

[7]  N. Ordóñez.  What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. , 2007, Human pathology.

[8]  K. Butnor.  My approach to the diagnosis of mesothelial lesions , 2006, Journal of Clinical Pathology.

[9]  Mutsuo Takahashi,et al.  Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion , 2006, Diagnostic cytopathology.

[10]  N. Ordóñez.  Value of Immunohistochemistry in Distinguishing Peritoneal Mesothelioma From Serous Carcinoma of the Ovary and Peritoneum: A Review and Update , 2006, Advances in anatomic pathology.

[11]  G. Pinkus,et al.  Monoclonal antibody MOC‐31 reactivity as a marker for adenocarcinoma in cytologic preparations , 2005, Cancer.

[12]  N. Ordóñez.  The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study , 2006, Modern Pathology.

[13]  C. Kandaraki,et al.  Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids , 2005, Diagnostic cytopathology.

[14]  A. Hjerpe,et al.  The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion , 2005, Diagnostic cytopathology.

[15]  Y. Gong,et al.  Immunocytochemistry of serous effusion specimens: A comparison of ThinPrep® vs. cell block , 2003, Diagnostic cytopathology.

[16]  M. Lozano,et al.  Immunocytochemistry in the differential diagnosis of serous effusions , 2001, Cancer.

[17]  B. D. De Young,et al.  MOC‐31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells , 1999, Cancer.

[18]  J. Katzmann,et al.  The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. , 1998, American journal of clinical pathology.

[19]  T. H. van der Kwast,et al.  Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions , 1997, Diagnostic cytopathology.

[20]  B. D. De Young,et al.  Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[21]  S. Poppema,et al.  Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. , 1994, Archives of pathology & laboratory medicine.

[22]  T. H. van der Kwast,et al.  Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma , 1991, The Journal of pathology.